Open AccessEffect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
Author(s) -
Paul D. Miller,
Gary Hattersley,
Bente Juel Riis,
Gregory C. Williams,
Edith Lau,
Luis Augusto Tavares Russo,
Peter Alexandersen,
Cristiano A. F. Zerbini,
Mingyi Hu,
Alan G. Harris,
Lorraine A. Fitzpatrick,
Felicia Cosman,
Claus Christiansen
Publication year - 2016
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2016.11136
Subject(s) - medicine , teriparatide , femoral neck , osteoporosis , placebo , clinical endpoint , bone mineral , surgery , randomized controlled trial , alternative medicine , pathology
Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom